Dr. Hang Shi's lab at Georgia State University focuses on understanding how an enzyme called HDAC1 affects liver health and diseases, specifically non-alcoholic fatty liver disease (NAFLD), which is linked to obesity and diabetes. The research investigates how HDAC1 contributes to fat buildup and inflammation in the liver, potentially leading to severe liver complications. By exploring the relationship between diet and epigenetic changes in the liver, the lab aims to identify new therapeutic strategies for treating NAFLD.

Dr. Jianliang Xu's lab focuses on developing innovative treatments for HIV using nanobodies, which are smaller and more versatile than traditional antibodies. The lab aims to create nanobodies that can target multiple sites on the HIV virus, potentially improving treatment effectiveness and simplifying administration. Their work could lead to breakthrough therapies that enhance the fight against AIDS and offer new hope for patients worldwide.